Effect of chronic disulfiram administration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjects

被引:36
作者
Frye, RF
Branch, RA
机构
[1] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA
[2] Univ Pittsburgh, Ctr Clin Pharmacol, Pittsburgh, PA 15261 USA
关键词
acetylation; caffeine; chlorzoxazone; cytochrome P450; dapsone; deacetylation; debrisoquine; disulfiram; mephenytoin;
D O I
10.1046/j.1365-2125.2002.01522.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims Short-term disulfiram administration has been shown to selectively inhibit CYP2E1 activity but the effects of chronic disulfiram administration on the activities of drug metabolizing enzymes is unclear. The purpose of this study was to evaluate the effects of disulfiram given for 11 days on selected drug metabolizing enzyme activities. Methods Seven healthy volunteers were given disulfiram 250 mg daily for 11 days. Activities of the drug metabolizing enzymes CYP1A2, CYP2C19, CYP2D6, CYP2E1 and N-acetyltransferase were determined using the probe drugs caffeine, mephenytoin, debrisoquine, chlorzoxazone, and dapsone, respectively. Chlorzoxazone was administered before disulfiram administration and after the second and eleventh doses of disulfiram, while the other probe drug, were given before disulfiram administration and after the eleventh disulfiram dose. Results Disulfiram administration markedly inhibited chlorzoxazone 6-hydroxylation by more than 95%, but did not affect metabolism of debrisoquine or mephenytoin. Caffeine N3-demethylation was decreased by 34% (P<0.05). Monoacetyldapsone concentrations were markedly elevated by disulfiram administration resulting in a nearly 16-fold increase in the dapsone acetylation index, calculated as the plasma concentration ratio of monoacetyldapsone to dapsone. CYP-mediated dapsone N-hydroxylation was not significantly altered. Conclusions These data suggest that disulfiram-mediated inhibition is predominantly selective for CYP2E1. The magnitude of CYP2E1 inhibition was similar after both acute and chronic disulfiram administration. The effects on caffeine N3-demethylation (CYP1A2) and dapsone metabolism suggest that chronic disulfiram administration may affect multiple drug metabolizing enzymes, which could potentially complicate the use of chronically administered disulfiram as a diagnostic inhibitor of CYP2E1.
引用
收藏
页码:155 / 162
页数:8
相关论文
共 41 条
[11]   A sensitive method for the simultaneous determination of caffeine and its dimethylxanthine metabolites in human plasma: Application to CYP1A2 phenotyping [J].
Frye, RF ;
Stiff, DD ;
Branch, RA .
JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES, 1998, 21 (08) :1161-1171
[12]   Use of chlorzoxazone as an in vivo probe of cytochrome P450 2E1:: Choice of dose and phenotypic trait measure [J].
Frye, RF ;
Adedoyin, A ;
Mauro, K ;
Matzke, GR ;
Branch, RA .
JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 38 (01) :82-89
[13]   SIMPLE AND RELIABLE CYP1A2 PHENOTYPING BY THE PARAXANTHINE/CAFFEINE RATIO IN PLASMA AND IN SALIVA [J].
FUHR, U ;
ROST, KL .
PHARMACOGENETICS, 1994, 4 (03) :109-116
[14]   N-hydroxylation of dapsone by multiple enzymes of cytochrome P450: Implications for inhibition of haemotoxicity [J].
Gill, HJ ;
Tingle, MD ;
Park, BK .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 40 (06) :531-538
[15]   ASSESSMENT OF CYTOCHROME P4502E1 INDUCTION IN ALCOHOLIC PATIENTS BY CHLORZOXAZONE PHARMACOKINETICS [J].
GIRRE, C ;
LUCAS, D ;
HISPARD, E ;
MENEZ, C ;
DALLY, S ;
MENEZ, JF .
BIOCHEMICAL PHARMACOLOGY, 1994, 47 (09) :1503-1508
[16]   BIOTRANSFORMATION OF CAFFEINE, PARAXANTHINE, THEOBROMINE AND THEOPHYLLINE BY CDNA-EXPRESSED HUMAN CYP1A2 AND CYP2E1 [J].
GU, L ;
GONZALEZ, FJ ;
KALOW, W ;
TANG, BK .
PHARMACOGENETICS, 1992, 2 (02) :73-77
[17]   ROLE OF HUMAN CYTOCHROME-P-450-IIE1 IN THE OXIDATION OF MANY LOW-MOLECULAR-WEIGHT CANCER SUSPECTS [J].
GUENGERICH, FP ;
KIM, DH ;
IWASAKI, M .
CHEMICAL RESEARCH IN TOXICOLOGY, 1991, 4 (02) :168-179
[18]   Dose dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine [J].
Jeppesen, U ;
Gram, LF ;
Vistisen, K ;
Loft, S ;
Poulsen, HE ;
Brosen, K .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 51 (01) :73-78
[19]  
KAISARY A, 1987, CANCER RES, V47, P5488
[20]  
Kharasch ED, 1999, DRUG METAB DISPOS, V27, P717